• Sanofi’s strategic acquisition of Vigil Neuroscience and the development of VG-3927, a novel oral TREM2 agonist designed to enhance microglial clearance of neurotoxic debris
• Recent clinical data from Phase 1 trials demonstrating safety, central nervous system penetration, and biomarker modulation supporting further clinical development
• The promise and challenges of TREM2-targeted therapies as potential disease modifying treatments that address neuroinflammation and microglial dysfunction beyond traditional protein-targeting approaches

CLINICAL UPDATE